UA90493C2 - Альфа-тимозиновые пептиды как адьюванты противораковых вакцин - Google Patents

Альфа-тимозиновые пептиды как адьюванты противораковых вакцин

Info

Publication number
UA90493C2
UA90493C2 UAA200707406A UAA200707406A UA90493C2 UA 90493 C2 UA90493 C2 UA 90493C2 UA A200707406 A UAA200707406 A UA A200707406A UA A200707406 A UAA200707406 A UA A200707406A UA 90493 C2 UA90493 C2 UA 90493C2
Authority
UA
Ukraine
Prior art keywords
cancer vaccine
alpha thymosin
vaccine adjuvants
subject
thymosin peptides
Prior art date
Application number
UAA200707406A
Other languages
English (en)
Ukrainian (uk)
Inventor
Густаво Антонио Мовиглиа
Альфред Р. Рудольф
Original Assignee
Сайклон Фармасютикалс, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклон Фармасютикалс, Инк filed Critical Сайклон Фармасютикалс, Инк
Publication of UA90493C2 publication Critical patent/UA90493C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается фармацевтической комбинации для лечения рака, которая содержит индуцирующую иммунный ответ противоопухолевую вакцину и повышающее эффективность вакцины количество альфа-тимозинового пептида, повышающего ответ иммунной системы у субъекта.
UAA200707406A 2004-12-06 2005-12-06 Альфа-тимозиновые пептиды как адьюванты противораковых вакцин UA90493C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
UA90493C2 true UA90493C2 (ru) 2010-05-11

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200707406A UA90493C2 (ru) 2004-12-06 2005-12-06 Альфа-тимозиновые пептиды как адьюванты противораковых вакцин

Country Status (15)

Country Link
US (1) US20100092499A1 (ru)
EP (1) EP1835931A4 (ru)
JP (1) JP2008523067A (ru)
KR (1) KR20070086663A (ru)
CN (1) CN101072582B (ru)
AU (1) AU2005314271B2 (ru)
BR (1) BRPI0518571A2 (ru)
CA (1) CA2588685A1 (ru)
EA (1) EA015510B1 (ru)
IL (1) IL183264A (ru)
MX (1) MX2007006717A (ru)
NO (1) NO20072705L (ru)
NZ (1) NZ555571A (ru)
UA (1) UA90493C2 (ru)
WO (1) WO2006062917A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
CN104507491A (zh) * 2012-03-08 2015-04-08 赛生制药有限公司 胸腺素α在治疗化脓性鼻窦炎中的应用
TWI749433B (zh) * 2014-10-21 2021-12-11 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
JP2004500029A (ja) * 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
MXPA04003864A (es) * 2001-10-26 2004-08-11 Immuno Rx Inc Inmunoterapia para revertir la supresion inmune.
DK1448223T3 (da) * 2001-10-26 2008-02-18 Rhode Island Hospital Thymosin-forögelse af genetisk immunisering
WO2004003174A2 (en) * 2002-06-28 2004-01-08 Sciclone Pharmaceuticals Inc. Method of up-regulating tumor antigen expression using thymalfasin
UA80870C2 (en) * 2003-03-28 2007-11-12 Sciclone Pharmaceuticals Inc Method for treatment or prevention of aspergillus infections with thymosin alpha 1
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
CN101072582A (zh) 2007-11-14
JP2008523067A (ja) 2008-07-03
AU2005314271B2 (en) 2011-06-16
MX2007006717A (es) 2007-08-06
NO20072705L (no) 2007-09-05
CA2588685A1 (en) 2006-06-15
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
AU2005314271A1 (en) 2006-06-15
IL183264A0 (en) 2007-09-20
NZ555571A (en) 2009-02-28
CN101072582B (zh) 2012-06-27
EP1835931A2 (en) 2007-09-26
EA015510B1 (ru) 2011-08-30
EA200701166A1 (ru) 2008-02-28
WO2006062917A3 (en) 2006-11-16
BRPI0518571A2 (pt) 2008-11-25
IL183264A (en) 2010-12-30
KR20070086663A (ko) 2007-08-27
EP1835931A4 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
UA90493C2 (ru) Альфа-тимозиновые пептиды как адьюванты противораковых вакцин
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
WO2006040076A3 (de) Impf-adjuvanzien pam3cys, poly (i:c), imiquimod, loxoribine, r-848 und cpg-dna zusammen mit mhc i oder mhc ii epitopen
WO2006042149A3 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2006007555A3 (en) Rotavirus antigens
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
WO2006039533A3 (en) Bcr-abl imatinib resistance-associated peptides and methods of use thereof
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2005085420A3 (de) Leukozytenstimulations-matrix
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
WO2003093298A3 (en) Immunogenic peptides
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine